Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Oral VXA-CoV2-1 Vaccine in Healthy Adults
NCT04563702Phase 1Completed
- Sponsor
- Vaxart, Inc.
- Start
- Sep 2020
- Primary completion
- Oct 2021
- Modality
- Viral Vector Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of VXA-CoV2-1 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Vaxart, Inc. Primary endpoints: Frequency of solicited symptoms of reactogenicity, Grade of solicited symptoms of reactogenicity and 3 more. Started Sep 2020; status: completed.
02
Drugs
VXA-CoV2-1
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04563702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04563702.